The following article, published in Pediatrics in April 2010, reports on a survey of perinatal hepatitis B prevention policies in 190 delivery hospitals across the United States. The study examined how well hospitals implemented national ACIP recommendations for perinatal hepatitis B virus (HBV) prevention. Survey results reveal serious gaps in hospital policies and practices regarding perinatal HBV transmission. The study concludes that "efforts to avoid medical errors through appropriate implementation and monitoring of hospital practices are needed to eliminate perinatal HBV transmission."
In the United States, an estimated 1.4 million people have chronic hepatitis B virus (HBV) infection, which is the underlying cause of 2000 to 4000 deaths annually. 1 Two primary modes of HBV transmission occur during infancy: infected mother to newborn during delivery and infected household contact to infant. In contrast to adults with an ϳ5% risk for chronic HBV infection once infected, infants have an ϳ90% risk for developing chronic HBV infection and when chronically infected have a 25% risk for dying prematurely of cirrhosis or liver cancer. An estimated 24 000 HBV-infected US women give birth annually (Centers for Disease Control and Prevention [CDC] , unpublished data, 2004). Prenatal screening of all pregnant women is recommended to identify hepatitis B surface antigen (HBsAg)-positive women before giving birth to ensure that their newborns can receive postexposure prophylaxis (PEP). 2 PEP includes the administration of hepatitis B vaccine (HepB) and hepatitis B immunoglobulin (HBIG) to newborns within 24 hours of birth and is 85% to 95% effective in preventing HBV transmission; HepB administration alone within the same time frame is 70% to 95% effective. 3, 4 Hepatitis B vaccination of newborns also provides preexposure protection to infants born to uninfected women when, if HBV exposure were to occur, the risk for developing chronic HBV infection is greatest. Newborn HepB administration is a key intervention to prevent perinatal HBV transmission and the subsequent morbidity and mortality that are caused by chronic HBV infection. 5 Despite the availability of PEP, infants continue to become infected. Approximately 40 to 90 perinatal HBV infections are reported to the CDC annually, 6, 7 although the true number of annual perinatal HBV infections may be 10 to 20 times higher. 7 Perinatal HBV infections may occur as a result of various health care errors, including prenatal testing and reporting, failure to test all women who are admitted to delivery hospitals without prenatal HBsAg test results, lapses in reporting and documentation of HBsAg test results in maternal and newborn medical records, 8 and failure to administer timely PEP.
The delivery hospital is the critical point for implementing perinatal HBV prevention activities; it is the safety net for ensuring that HBV-infected women are identified at delivery and it is where time-sensitive PEP must be delivered to the newborn. Delivery hospitals also play an important role in reporting HBsAg-positive women to health departments to ensure that infants complete the HepB series, undergo postvaccination serologic testing, and, if infected, are referred for evaluation and care. In December 2005, the Advisory Committee on Immunization Practices (ACIP) published recommendations to address the remaining challenges in prevention of perinatal transmission of HBV. 4 To assess hospital policies and practices pertaining to perinatal HBV prevention, we conducted a nationally representative assessment that included a survey of hospital policies and medical record reviews.
METHODS

Sample Selection
The target population included all delivery hospitals in the 50 states, District of Columbia, and Puerto Rico as identified in the 2003 American Hospital Association (AHA) annual survey. Fifty-two percent of all hospitals (n ϭ 3102) were eligible for selection based on number of births (Ͼ100 annually), accounting for 99.5% of births reported by hospitals in the AHA survey. With simple random sampling, a sample size of 200 hospitals was needed to estimate the proportion of hospitals reporting a given policy with a 95% confidence interval (CI) Ϯ 7 percentage points. We allocated the sample size across 51 strata (50 states plus 1 stratum containing Washington, DC, and Puerto Rico) proportional to the number of hospitals in each stratum. When the number of hospitals allocated to a given stratum was Ͻ2, the selection of 2 was forced to calculate variance estimation on the basis of the sample design. We sampled 254 hospitals to allow for an ϳ80% response rate. Hospitals were contacted to verify provision of delivery services and to identify a contact person for survey receipt. Twelve hospitals did not provide delivery services, leaving a final sample of 242.
Hospital Policy Survey
The 
Data Collection
Hospital survey and medical record data were collected by the designated hospital contact, state or local health department staff, or, in the majority of cases, a combination of both. The majority of participating health department staff provided assistance by conducting follow-up telephone calls to ensure survey receipt and completion.
Data Analysis
We conducted the following descriptive analyses: (1) prevalence of policies regarding prevention of perinatal HBV transmission; (2) factors that were associated with prenatal testing; (3) prevalence of maternal HBV infection; (4) HepB and HBIG receipt within 12 hours of delivery for infants who were born to women with HBsAgpositive or unknown status, according to ACIP recommendations 4 ; and (5) maternal and facility characteristics associated with HepB receipt at birth. We also compared maternal HBsAg test results that were documented in the maternal medical record from prenatal and on-admission testing, as well as maternal results that were documented in the infant's medical record.
Among mother-infant pairs with any mention of a positive maternal HBsAg test result, we defined 2 subsets. First, for estimation of the national prevalence of HBV infection, pregnant women were considered infected when they had documentation of a positive HBsAg test result prenatally or on admission and when there were no contradictory results in any records (eg, women who were HBsAg-positive prenatally but HBsAg-negative according to infant medical record were excluded). Second, for assessment of management of infants of HBsAgpositive mothers who were identified prenatally, data on all infants whose mothers had a documented HBsAgpositive prenatal test result were included.
Hospital survey data were weighted according to inverse probability of hospital selection and adjusted for nonresponse. For data analysis of mother-infant pairs, hospitals were identified as primary sampling units and results were weighted according to the number of annual live births in the respective hospitals. Analyses were conducted by using SUDAAN 903 to account for the stratified survey design. Weighted proportions and raw numbers are reported throughout.
RESULTS
Response Rate
Of 242 sampled hospitals, 190 (78.5%) completed the policy survey and medical record review. Hospital response rates by state ranged from 0% to 100% (100% of sampled hospitals in 32 states, 75%-99% in 8 states, 50%-74% in 8 states, 28% in 1 state, and 0% [among 12 hospitals] in 3 states). The median number of responding hospitals by state was 3 (range: 1-10). There were no statistically significant differences between responding and nonresponding hospitals regarding annual number of live births, hospital funding type (profit/not for profit) and urban/ rural location. Medical record reviews were completed for 4762 mothers and 4786 infants (24 twins) who were born January 2005 through December 2006.
Policies for Perinatal Hepatitis B Prevention
The proportion of hospitals reporting each of the 6 policies examined ranged from 63.0% to 80.6% ( 
Maternal Characteristics and HBsAg Screening
The majority of the 4762 women were white, privately insured, and 18 to 25 years of age (Table 2) . Prenatal HBsAg test results were documented in 92.6% (95% CI: 90.4 -94.3) of maternal medical records and varied little by demographic characteristic. HBsAg test results were documented by copy of the laboratory report in 12.8% (95% CI: 9.6 -16.9) of maternal medical records reviewed; documentation in the re- 
Prevalence of Maternal HBV Infection
Twenty-one women had documentation of a positive HBsAg prenatal test (n ϭ 18) or tested positive on admission (n ϭ 3) for an overall weighted prevalence of 0.9% (95% CI: 0. Table 3) . 
Documentation of Maternal HBsAg Status and Discrepant Test Results
Universal Newborn HepB Vaccination
Overall, 68.7% (95% CI: 59.4 -76.6) of infants received HepB at birth. Most strongly associated with vaccine administration was having a written hospital policy for HepB administration at birth and hospital location in a state with a universal birth dose policy. 9 Other significant factors included maternal insurance carrier (Medicaid), hospital affiliated with a medical residency program, and rural location (Table 5) . Table 4 ). b Infants who were born to mothers with no documentation of prenatal HBsAg test result.
A
DISCUSSION
We conducted a national survey of hospitals to determine policies for prevention of perinatal HBV transmission and conducted medical record reviews for almost 5000 mother-infant pairs. Management of HBV-exposed infants and infants born to women with unknown HBsAg status was suboptimal in this study. For HBV-exposed infants, comparisons with past studies are difficult because the number of HBVexposed infants in this study and others is small. In the study by Yusuf et al, 13 9 of 12 exposed infants were vaccinated and 8 of 12 received HBIG (timing unspecified). In the study by Pierce et al, 10 7 of 9 were vaccinated within 24 hours (HBIG administration not reported). Administration of HepB to infants who were born to women with unknown HBsAg status was higher in this study than in that reported by Yusuf et al (22%). Administration of HBIG to infants who weighed Ͻ2000 g and were born to women with unknown status was very low in this study. Whereas the American Academy of Pediatrics has recommended that these infants receive HBIG since 1997, 15 the ACIP adopted the recommendation only in 2005. 4 Errors in the transcription of maternal HBsAg status have been well documented 8 ; as a result, the revised 2005 ACIP statement recommends that a copy of the original laboratory report indicating HBsAg status be included in both the maternal and infant medical records. Of the 27 mother-infant pairs in our sample with any documentation of a positive maternal HBsAg test result (Table 4) , maternal results in the infant medical records were discrepant or missing for 15, demonstrating a medical documentation error rate of Ͼ50%. This is alarming, particularly when one considers that these errors were identified only among motherinfant pairs with any documentation of A potential reason for the difference between these 2 estimates is that this study included data that were collected directly from infant hospital medical records, whereas in the NIS, vaccination coverage was obtained from outpatient pediatric provider medical records. The latter might not always have records of hospital-administered HepB. Random error and systematic biases in either survey may also contribute to the differences.
The estimated HBsAg-positive prevalence among pregnant women in this assessment was 0.9% (95% CI: 0.5-1.8) compared with 0.4% (95% CI: 0.2-0.8) in the 1993 study 13 ; however, this difference is not statistically significant. Given differences in the proportion of mothers with known HBsAg status between the 2 assessments and discrepancies in HBsAg test result documentation discussed, ascertainment of true infection rate from a medical record review is challenging.
There is a growing need for implementation of perinatal HBV prevention practices by delivery hospitals given that the number of births to foreign-born women is increasing. In 2004, 24% of all US births were to foreign-born women compared with 18% in 1993. 17 In addition, immigra- a Totals may vary; missing and "don't know" responses were excluded. b Policy to provide the newborn HepB dose at no cost to all infants, regardless of insurance status. c Infants who weighed Ͻ2000 g at birth and were born to HBsAg-negative mothers were excluded.
A tion from countries with high endemicity has increased. 1, 18 There are certain limitations to these findings. First, personnel who conducted data collection varied, with the majority of medical record abstractions conducted by health department staff and the remainder by hospital personnel. Second, although the overall response rate was high, 2 large states, California and Texas, had low hospital participation rates, which could affect the representativeness of the data. Third, this study was not designed to follow infants who were born to HBsAg-positive mothers to determine perinatal HBV infection rate.
CONCLUSIONS
Given the existence of highly effective PEP, perinatal HBV transmission can be almost entirely prevented, but gaps in the delivery hospital prevention policies and practices persist. Universal newborn HepB vaccination, together with timely administration of appropriate prophylaxis to infants who are born to HBsAg-positive women and women of unknown HBsAg status, are essential hospital clinical practices for preventing perinatal HBV infections. In October 2008, the National Quality Forum endorsed 2 perinatal care performance measures specific to HepB, 19 1 to monitor hospital newborn HepB coverage and a second to monitor the proportion of infants who are born to HBsAg-positive women and receive timely and appropriate prophylaxis in delivery hospitals. Although use of National Quality Forum performance measures is a promising step toward closing the persistent hospital gaps for perinatal HBV prevention in the United States, considerable work remains.
